Peroxisome proliferator-activated receptors (PPARs) are nuclear receptor isoforms with key roles in the regulation of lipid and glucose metabolism. Synthetic ligands for PPARg (and PPARa) have effects of promoting insulin sensitization in the context of obesity. Recent evidence suggests that activation of PPARd might produce similar effects. Both PPARg and PPARa have also been shown to produce selected anti-inflammatory effects and to reduce the progression of atherosclerosis in animals (a and g) or in humans (a). Mechanisms underlying insulin-sensitizing effects are complex. For PPARg, direct effects on adipose tissue lipid metabolism with secondary benefits in liver and/or muscle (lipid levels and insulin signaling) have been implicated. For PPARa, accelerated lipid catabolism may contribute to reduced muscle or liver 'steatosis'. Anti-inflammatory mechanisms as contributors to the beneficial metabolic effects of PPAR activation are also worth considering for the following reasons: (1) obesity and insulin resistance are associated with a proinflammatory milieu. (2) PPARg has clear effects to oppose the effects of tumor necrosis factor-alpha (TNFa) in adipocytes. (3) effects of PPAR ligands on cytokine-mediated signaling (eg via NF-kB) may be expected to enhance insulin action. (4) Adipose production of several molecules that are implicated as markers or mediators of inflammation is reduced. (5) In humans, treatment with either PPARa or PPARg agonists has been shown to reduce circulating levels of proteins that serve as markers of inflammation. (6) Adiponectin, a fat-derived circulating factor that has been implicated as having anti-inflammatory activity, is induced by PPARg agonism.
Introduction
The peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily. Three isoforms, encoded by separate genes, have been identified thus far: PPARg, PPARa, and PPARd (also known as PPARb). The PPARs are ligand-dependent transcription factors that regulate target gene expression by binding to specific peroxisome proliferator response elements (PPREs) in enhancer sites of regulated genes. Each receptor binds to its PPRE as a heterodimer with a retinoid X receptor (RXR). Upon binding an agonist, the conformation of a PPAR is altered and stabilized such that a binding cleft is created and recruitment of transcriptional coactivators occurs. The result is an increase in gene transcription. Figure 1 illustrates the basic mechanism of PPAR activation. Fatty acids and their derivatives including a variety of eicosanoids and prostaglandins have been implicated as natural ligands and agonists of the PPARs. Therefore, the general actions of PPARs apparently have a central role in the sensing of nutrient levels and in the modulation of their metabolism.
Importantly, it is clear that PPARs are primary targets of two key classes of synthetic compounds that have been used in the successful treatment of diabetes and dyslipidemia. Specifically, thiazolidinedione (TZD) insulin sensitizers (rosiglitazone and pioglitazone) are potent and specific PPARg ligands and activators. Fibrates, which include fenofibrate, clofibrate, ciprofibrate, and gemfibrozil, have predominant activity as PPARa agonists; this activity is viewed as the principal mechanism of their favorable effects on lipids. Both PPARa and PPARg have also been implicated as having substantial anti-inflammatory actions. In this regard, it is important to note that both PPARg agonists (in rodent models) and PPARa agonists (in both rodents and humans) have been demonstrated to improve the course of atherosclerotic cardiovascular disease. In addition to the insulin-sensitizing efficacy of PPARg activation, recent results also suggest that insulin-sensitizing effects can occur as a consequence of PPARa or PPARd activation.
The subject of this review is to address the mechanisms by which PPARs mediate insulin-sensitizing efficacy, with particular attention to the potential role of anti-inflammatory actions in contributing to these mechanisms.
Insulin-sensitizing effects of PPAR ligands
PPARg agonists that include both TZD and non-TZD chemical classes have in vivo insulin-sensitizing and antidiabetic effects in animals and in humans. 1 The existence of a general correlation between in vitro PPARg potency and in vivo insulin-sensitizing efficacy strongly supports PPARg activation as being the primary molecular mechanism for the efficacy of these chemically diverse synthetic compounds. The finding of human kindreds with inherited insulin resistant type II diabetes caused by PPARg dominantnegative mutations confirms a key role for PPARg in the regulation of systemic insulin action.
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PPARg is expressed as two isoforms (g1 and g2) that differ due to the addition of 30 amino acids at the PPARg2 Nterminus. Both PPARg isoforms are most highly expressed in adipose tissue (PPARg2 is specific to this tissue). Moreover, it has been clearly shown that PPARg is both necessary and sufficient for the differentiation of adipocytes. 3 The activation of PPARg in adipocytes induces the expression of many PPRE-containing genes that are involved in lipid metabolism. These include fatty acid-binding protein 4 (FABP4; aP2), PEPCK, acyl-CoA synthase, lipoprotein lipase, and fatty acid transporters such as FATP-1 and CD36. 3 Pathways that have been suggested to contribute to PPARgmediated increases in systemic insulin action are illustrated in Figure 2 . Systemic activation of PPARg in insulin-resistant animals or humans results in a gradual increase in the sensitivity of liver to insulin-mediated suppression of hepatic glucose production and in the sensitivity of muscle to insulin-mediated glucose uptake and storage or metabolism. 4 These effects are believed to be caused by the reversal of selected defects in the proximal insulin signaling pathway such as impaired tyrosyl phosphorylation of IRS proteins and reduced phosphatidyl inositol 3-kinase (PI-3-kinase) activity. Given that PPARg is expressed predominantly in adipose tissue, we have speculated that its in vivo effects on insulin signaling and action in liver and muscle were due primarily to gene regulation in this tissue and that the effects in liver and muscle were secondary. This hypothesis was supported by the observation that rosiglitazone failed to lower glucose in a mouse model of severe insulin resistance where white adipose tissue was ablated. 5 We have also observed that in vivo treatment of insulin-resistant rodents produces rapid normalization of adipose tissue insulin action, whereas improved insulin sensitivity in muscle (or liver) was not evident until several days after the initiation of therapy (see Zierath et al 6 and T Doebber, unpublished). These results are also consistent with the fact that PPARg agonists can produce an increase in adipose tissue insulin action after direct in vitro incubation, 7 whereas no such effect could be demonstrated using isolated in vitro incubated skeletal muscles. 6 Local increases in adipose insulin sensitivity may be mediated by the induction of selected signaling molecules by PPARg such as c-CBL-associated protein or IRS2. 3 In addition, we recently showed that PPARg agonists downregulate the expression of 11b-hydroxysteroid dehydrogenase 1 (11b-HSD-1) in adipocytes. 8 This enzyme regulates the conversion of cortisone to cortisol, thereby controlling local glucocorticoid action. Since hypercorticosteroidism is a known cause of insulin resistance and since transgenic and knockout experiments have validated 11b-HSD-1 as a key regulator of in vivo insulin sensitivity, 9 it is plausible that some of the insulin-sensitizing actions of PPARg agonism could be caused by decreased adipose 11b-HSD-1 levels. An obvious way by which local effects in adipose tissue can result in reduced insulin resistance in distant sites involves the ability of PPARg agonists to augment insulin-mediated adipose tissue uptake, storage (and potentially catabolism) of free fatty acids -(FFAs). 3, 10 This results in lowering of circulating FFAs and a more gradual reduction in liver and/ or muscle steatosis, which are now well-described aspects of the pathogenesis of insulin resistance. Changes in adipose-derived circulating factors that could either promote or reduce insulin resistance are also likely to have a role in contributing to the net benefits of PPARg activation. Candidate mediators include 'resistin' or adiponectin and tumor necrosis factor (TNF)-a, which are discussed below. PPARa is expressed in numerous metabolically active tissues including the liver, kidney, heart, skeletal muscle, and brown fat. 3 PPARa has been shown to play a critical role in the regulation of cellular uptake, activation, and b-oxidation of fatty acids. Thus, PPARa induces the expression of the fatty acid transporters and enzymes, which contribute to fatty acid catabolism such as lipoprotein lipase, fatty acid acetyl-CoA synthase, acyl-CoA oxidase, and carnitine palmitoyltransferase I. 3 The well-described effects of fibrates to lower triglyceride levels are clearly mediated by PPARa activation based upon studies performed in PPARa-null mice. In addition to their effects to treat dyslipidemia effectively, selected PPARa ligands have also been shown to exert antidiabetic and insulin-sensitizing effects. 11, 12 The mechanisms underlying such effects are likely to involve a reduction in hepatic or muscle lipid content 12 , although additional mechanisms may pertain as discussed below.
Interestingly, PPARd, which is more widely expressed, has also been suggested to have some role in regulating insulin action. This is based mostly on the recent discovery of a highly potent and selective agonist, GW501516. Treatment of obese monkeys with this agent ameliorated hyperinsulinemia. 13 
PPAR ligands have antiatherosclerotic and antiinflammatory effects
Antiatherosclerosis effects Both PPARg and PPARa are known to be expressed in cell types relevant to the regulation of immune function and to the pathogenesis of atherosclerosis. These include monocytes, macrophages, vascular smooth muscle, and vascular endothelial cells. 3 Importantly, human clinical trials have shown an effect of fibrates (PPARa agonists) to reduce the progression of atherosclerosis. 14 Interestingly, the reduction in cardiovascular morbidity and mortality seen with one such agent, gemfibrozil, was greater than the modest changes in triglycerides or HDL cholesterol would have predicted. 14 Thus, other mechanisms such as anti-inflammatory effects have been implicated. In several studies using mouse or rabbit models of accelerated atherogenesis, TZD PPARg agonists were shown to produce substantial decreases in lesion size. 3 A potential antiinflammatory mechanism was suggested by a reduction in monocyte-macrophage homing to arterial lesions in apo-Enull mice. 15 
Effects of PPARa ligands on inflammation
Earlier studies suggested that PPARa activation inhibited the inflammatory action of eicosanoids since one such molecule, leukotriene B4 (LTB4), a potent chemotactic agent, was found to be a ligand and agonist for the receptor. 16 More recently, PPARa ligands have been shown to produce a range of anti-inflammatory effects in important cell types. These effects included the induction of apoptosis in cytokine-activated macrophages, inhibition of NF-kB signaling in aortic smooth muscle cells, and decreased plasma concentrations of the inflammatory cytokine interleukin-6 in fibrate-treated humans. 17 In addition, IkBa levels were induced in vascular smooth muscle cells by fibrates thereby offering another anti-inflammatory mechanism.
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Anti-inflammatory effects of PPARc ligands
The effects of PPARg agonists to ameliorate atherosclerosis in animal models occur despite a lack of apparent effects on circulating metabolic parameters. This suggests that other mechanisms (eg anti-inflammatory) are involved. TZDs can also impart some degree of efficacy in animal models of arthritis and inflammatory bowel disease. Although PPARg is strongly expressed upon the differentiation of monocytes into macrophages, recent results using knockout cells have clearly established that PPARg is not necessary for macrophage differentiation. 18 The potential anti-inflammatory role of PPARg in macrophages has been quite controversial. Earlier results obtained using higher concentrations of TZDs or another PPARg ligand, 15-deoxy-D 12,14 prostaglandin J 2 (15d-PG J 2 ), found strong repression of cytokine (TNFa or IL-6) production by cultured macrophages. 18 However, we and others have failed to replicate these results or to observe suppression of TNFa levels in LPS-challenged mice. 19 Moreover, 15d-PG J 2 has now been shown to have non-PPARmediated effects on cytokine signaling and the effects of TZDs on cytokine production are retained in murine PPARgnull macrophages. 18 The above results do not exclude an anti-inflammatory role for PPARg, but only serve to confirm that PPARg does not specifically repress cytokine production by macrophages. Additional putative anti-inflammatory effects that have been reported using PPARg ligands and agonists include: (a) reduced expression of chemokine receptors (CCR2) in monocyte-macrophages; (b) accelerated macrophage apoptosis; and, (c) reduced expression of gelatinase B (MMP-9), which has an important role in degradation of the extracellular matrix and monocyte invasion. 18 A particular effect of either PPARa or PPARg activation to inhibit cytokineinduced vascular cell adhesion and to suppress monocytemacrophage migration has also been recently reported as a possible mechanism of antiatherosclerosis efficacy. 18 Importantly, several studies have also suggested that PPARg (like PPARa) activation in selected cell types can repress NFkB, and therefore cytokine-mediated, signaling. This notion was further bolstered by the observation of reduced NFkB activity (and suppressed adhesion molecule expression) in cells that were engineered to express a constitutively active form of PPARg.
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Potential connections between PPAR activation, anti-inflammatory activity, and insulin sensitization
Insulin resistance, obesity, and type II diabetes (ie 'metabolic syndrome') are known to be associated with a proinflammatory state and a high risk of accelerated atherosclerosis. Markers of inflammation that are increased in these disease states include acute-phase reactants (fibrinogen, C-reactive protein, a1 acid glycoprotein, and serum amyloid A3) and cytokines such as IL-6 and TNFa. 21, 22 Several of these proteins are expressed in adipose tissue where their respective expression levels may be increased in association with obesity, insulin resistance, and/or hyperglycemia. 22, 23 Indeed, TNFa has been implicated as a key mediator of insulin resistance via its effects to diminish insulin signal transduction. 23 Although PPARg agonists may not downregulate TNFa production in activated macrophages (see above), the expression of TNFa mRNA in adipose tissue of obese rodents was reduced by TZD treatment. 23 Importantly, we and others have clearly shown that PPARg agonists can potently inhibit the actions of TNFa in adipocytes. Thus, TNFa's ability to inhibit insulin signaling or to downregulate glucose transporter expression and glucose transport can be ablated by exposing adipocytes to PPARg agonists. 23 In addition, treatment of mice with troglitazone was shown to inhibit TNFa-induced insulin resistance. 24 Taken together, these results suggest that an important contributor to the insulin-sensitizing efficacy of PPARg ligands involves suppression of local TNFa production by adipocytes, a reduction in TNFa action in adipose tissue, and the potential for repression of selected adverse effects of TNFa in other tissues. Interestingly, we have recently observed that adipocyte expression of additional proinflammatory markers, including serum amyloid A3 and a-1 acid glycoprotein, is reduced in response to the treatment of cells with PPARg agonists (see Lin et al 22 and J Berger, unpublished). In addition, elevated levels of adipose a-1 acid glycoprotein expression in adipose tissue from db/db mice were normalized by in vivo PPARg agonist treatment. An additional molecule of potential relevance to this discussion is adipocyte-related complement protein of 30 kDa (adiponectin). Adiponectin is a secreted adipocytespecific protein that was recently shown to have in vivo effects, including decreased glucose, decreased triglycerides and FFAs. 25 Importantly, adiponectin has been implicated as having anti-inflammatory and/or antiatherosclerosis activities. 26, 27 Circulating levels are low in association with obesity, insulin resistance, and atherosclerosis and this protein may have actions to suppress vascular cell proliferation or macrophage function. We and others have recently shown that PPARg agonists can act to increase plasma levels of adiponectin in rodent models, normal human subjects, or humans with obesity and type II diabetes. 28 Thus, induction of adiponectin by PPARg agonists might have a key role in the mechanism(s) by which these drugs ameliorate aspects of metabolic syndrome and atherosclerosis.
Beyond the potential connections between metabolic efficacy and anti-inflammatory mechanisms described above, it is noteworthy that, like the effects of fibrates in patients with dyslipidemia, treatment of diabetic patients with TZD drugs has been shown to reduce circulating levels of proinflammatory markers such as C-reactive protein 29 and a1 acid glycoprotein. 30 Moreover, mononuclear cells derived from patients treated with troglitazone or rosiglitazone have reduced NFkB activity. 29, 31 
